Related Experiment Video
Updated: May 2, 2026
Simplified Whole Body Plethysmography to Characterize Lung Function During Respiratory Melioidosis
Published on: February 24, 2023
Comparative Burkholderia pseudomallei natural history virulence studies using an aerosol murine model of infection
Shane Massey1, Linsey A Yeager2, Carla A Blumentritt1
1Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, 77555.
Abstract:
Melioidosis is an endemic disease caused by the bacterium Burkholderia pseudomallei. Concerns exist regarding B. pseudomallei use as a potential bio-threat agent causing persistent infections and typically manifesting as severe pneumonia capable of causing fatal bacteremia. Development of suitable therapeutics against melioidosis is complicated due to high degree of genetic and phenotypic variability among B. pseudomallei isolates and lack of data establishing commonly accepted strains for comparative studies. Further, the impact of strain variation on virulence, disease presentation, and mortality is not well understood. Therefore, this study evaluate and compare the virulence and disease progression of B. pseudomallei strains K96243 and HBPUB10303a, following aerosol challenge in a standardized BALB/c mouse model of infection. The natural history analysis of disease progression monitored conditions such as weight, body temperature, appearance, activity, bacteremia, organ and tissue colonization (pathological and histological analysis) and immunological responses. This study provides a detailed, direct comparison of infection with different B. pseudomallei strains and set up the basis for a standardized model useful to test different medical countermeasures against Burkholderia species. Further, this protocol serves as a guideline to standardize other bacterial aerosol models of infection or to define biomarkers of infectious processes caused by other intracellular pathogens.
Insights
This study compares two Burkholderia pseudomallei strains in mice to understand melioidosis disease progression. Findings establish a standardized model for testing melioidosis therapeutics and understanding bacterial virulence.
Area of Science:
- Microbiology
- Infectious Diseases
- Pathogen Virulence Studies
Background:
- Melioidosis, caused by Burkholderia pseudomallei, is a significant public health concern due to its potential as a bio-threat agent.
- B. pseudomallei exhibits considerable genetic and phenotypic variability, complicating the development of effective therapeutics and understanding of disease.
- The impact of strain variation on melioidosis virulence, clinical presentation, and mortality remains poorly understood.
Purpose of the Study:
- To directly compare the virulence and disease progression of two distinct B. pseudomallei strains (K96243 and HBPUB10303a).
- To establish a standardized BALB/c mouse model for evaluating B. pseudomallei infection dynamics following aerosol challenge.
- To provide a foundation for testing medical countermeasures against Burkholderia species and defining biomarkers for intracellular pathogen infections.
Main Methods:
- Standardized BALB/c mouse model challenged via aerosol with B. pseudomallei strains K96243 and HBPUB10303a.
- Natural history analysis monitoring weight, body temperature, activity, and clinical signs.
- Comprehensive assessment including bacteremia, pathological and histological analysis of organ/tissue colonization, and immunological responses.
Main Results:
- Detailed comparative analysis of disease progression and host response between the two B. pseudomallei strains.
- Characterization of key parameters including bacterial load, tissue tropism, and inflammatory markers.
- Identification of strain-specific differences in virulence and pathogenesis.
Conclusions:
- The study successfully established and validated a standardized mouse model for B. pseudomallei aerosol infection.
- Direct comparison of strains provides critical data on the impact of variability on melioidosis pathogenesis.
- This model serves as a crucial platform for the development and evaluation of novel anti-melioidosis therapies and diagnostic biomarkers.
